1. Home
  2. MHO vs RCUS Comparison

MHO vs RCUS Comparison

Compare MHO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MHO

M/I Homes Inc.

HOLD

Current Price

$121.66

Market Cap

3.3B

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$22.83

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHO
RCUS
Founded
1976
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
2.8B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
MHO
RCUS
Price
$121.66
$22.83
Analyst Decision
Strong Buy
Buy
Analyst Count
2
11
Target Price
$160.00
$30.27
AVG Volume (30 Days)
178.2K
961.1K
Earning Date
04-22-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
14.74
N/A
Revenue
$4,417,781,000.00
$247,000,000.00
Revenue This Year
$0.66
N/A
Revenue Next Year
$6.97
$70.88
P/E Ratio
$8.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$100.22
$7.06
52 Week High
$158.92
$26.40

Technical Indicators

Market Signals
Indicator
MHO
RCUS
Relative Strength Index (RSI) 36.85 56.62
Support Level $118.03 $20.35
Resistance Level $140.41 $24.62
Average True Range (ATR) 3.45 1.05
MACD 0.06 0.01
Stochastic Oscillator 30.08 85.80

Price Performance

Historical Comparison
MHO
RCUS

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: